{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Paraproteinemia&page=8", "query": { "condition": "Paraproteinemia", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 2535, "total_pages": 254, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Paraproteinemia&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Paraproteinemia&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T03:27:48.407Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00545519", "title": "A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Or Refractory Multiple Myeloma" ], "interventions": [ { "name": "thymoglobulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2006-10", "completion_date": "2008-03", "has_results": false, "last_update_posted_date": "2013-04-23", "last_synced_at": "2026-10-21T03:27:48.407Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00545519" }, { "nct_id": "NCT00002630", "title": "High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "low-LET cobalt-60 gamma ray therapy", "type": "RADIATION" }, { "name": "low-LET photon therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 50, "start_date": "1993-06", "completion_date": "2001-05", "has_results": false, "last_update_posted_date": "2011-05-11", "last_synced_at": "2026-10-21T03:27:48.407Z", "location_count": 2, "location_summary": "Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002630" }, { "nct_id": "NCT00861510", "title": "A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Mantle-cell", "Leukemia, Lymphocytic, Chronic, B-Cell", "Leukemia, Hairy Cell", "Waldenstrom Macroglobulinemia", "Multiple Myeloma" ], "interventions": [ { "name": "ON01910 Na", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 16, "start_date": "2009-03-05", "completion_date": "2012-10-19", "has_results": false, "last_update_posted_date": "2019-12-03", "last_synced_at": "2026-10-21T03:27:48.407Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00861510" }, { "nct_id": "NCT06953960", "title": "A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Surzetoclax", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Etentamig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 325, "start_date": "2025-07-23", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-21T03:27:48.407Z", "location_count": 12, "location_summary": "Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06953960" }, { "nct_id": "NCT05623020", "title": "A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elranatamab", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1060, "start_date": "2022-11-10", "completion_date": "2033-10-03", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-21T03:27:48.407Z", "location_count": 17, "location_summary": "Jupiter, Florida • Lincoln, Nebraska • Reno, Nevada + 10 more", "locations": [ { "city": "Jupiter", "state": "Florida" }, { "city": "Lincoln", "state": "Nebraska" }, { "city": "Reno", "state": "Nevada" }, { "city": "Reno", "state": "Nevada" }, { "city": "Reno", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT05623020" }, { "nct_id": "NCT00911859", "title": "A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Siltuximab11 mg/kg", "type": "DRUG" }, { "name": "Siltuximab 8.3 mg/kg or 11 mg/kg", "type": "DRUG" }, { "name": "Velcade (bortezomib)", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 118, "start_date": "2009-06", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2014-11-18", "last_synced_at": "2026-10-21T03:27:48.407Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00911859" }, { "nct_id": "NCT00719888", "title": "Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Biphenotypic Leukemia", "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Burkitt Lymphoma", "Chronic Lymphocytic Leukemia", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Follicular Lymphoma", "Lymphoblastic Lymphoma", "Lymphoplasmacytic Lymphoma", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma", "Myelodysplastic Syndrome", "Myelofibrosis", "Non-Hodgkin Lymphoma", "Plasma Cell Myeloma", "Prolymphocytic Leukemia", "Refractory Anemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Double-Unit Umbilical Cord Blood Transplantation", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Umbilical Cord Blood Transplantation", "type": "PROCEDURE" }, { "name": "Thiotepa", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "65 Years", "sex": "ALL", "summary": "6 Months to 65 Years" }, "enrollment_count": 135, "start_date": "2005-11-18", "completion_date": "2024-12-19", "has_results": true, "last_update_posted_date": "2025-03-07", "last_synced_at": "2026-10-21T03:27:48.407Z", "location_count": 3, "location_summary": "Aurora, Colorado • Seattle, Washington", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00719888" }, { "nct_id": "NCT00726869", "title": "A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elotuzumab (HuLuc63)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2008-05", "completion_date": "2012-03", "has_results": false, "last_update_posted_date": "2012-08-23", "last_synced_at": "2026-10-21T03:27:48.407Z", "location_count": 8, "location_summary": "Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00726869" }, { "nct_id": "NCT01744912", "title": "Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkins Lymphoma", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "B-cell Lymphomas", "Marginal Zone Lymphoma", "Mantle Cell Lymphoma", "Waldenstrom's Macroglobulinemia" ], "interventions": [ { "name": "Ublituximab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TG Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2012-11-21", "completion_date": "2014-02-07", "has_results": false, "last_update_posted_date": "2022-05-11", "last_synced_at": "2026-10-21T03:27:48.407Z", "location_count": 2, "location_summary": "Huntsville, Alabama • Bethesda, Maryland", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01744912" }, { "nct_id": "NCT03110822", "title": "A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Ruxolitinib Oral Tablet [Jakafi]", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 134, "start_date": "2017-02-01", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2023-11-01", "last_synced_at": "2026-10-21T03:27:48.407Z", "location_count": 13, "location_summary": "Alhambra, California • Bakersfield, California • Encinitas, California + 9 more", "locations": [ { "city": "Alhambra", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03110822" } ] }